Waters provides financials for acquired BD Biosciences & Diagnostic Solutions; Q1 rev $766M

WATERS CORP /DE/

Acquisition closed Feb 9, 2026 via Reverse Morris Trust; Waters paid $4B cash distribution to BD.
BDS Business Q1 FY2026 net sales $766M (down 8% YoY from $834M); net income $49M vs $78M.
Operating income fell to $35M from $94M; includes $4M integration, restructuring & transaction costs.
Pro forma condensed combined financials as of Dec 31, 2025 and for FY2025 filed as Exhibit 99.4.
MD&A for fiscal years 2023-2025 and Q1 FY2026 provided; historical allocations may not reflect stand-alone costs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.